Immunomonitoring Laboratory (IML)
Natural and therapeutically induced immune responses to cancer can prevent and/or facilitate cancer development/outgrowth. New cancer immunotherapies have shown remarkable capacities to induce durable responses in patients with advanced forms of cancer (such as stage IV melanoma) that are generally resistant to any other types of cancer therapy. These findings have significantly changed the thinking about cancer treatment and about using the immune system as an important and effective weapon against cancer.
A centralized immune monitoring facility was launched in 2014 to facilitate translation of basic immune system research findings into the cancer immunotherapy arena, to support ongoing and new clinical cancer immunotherapy trials and to develop novel mechanistic insights into human immune system-cancer interactions. IML provides the means to monitor developing immune responses to new therapies in animal models of cancer treatment; to elucidate novel treatment strategies; or develop unique processes to evaluate treatment outcomes in translational studies. This shared resource provides the infrastructure and expertise to advance cancer immunotherapy outcomes.
- Produce custom human and murine MHC I tetramers
- Conjugate and validate mAbs and tetramers with metal-containing polymer tags or fluorophores
- Provide comprehensive immune monitoring including cytokine and biomarker quantitation, lymphocyte functional assays and serum antibody analysis (ELISA, ELISPOT and multiplex MSD quantitation)
- Promote identification of new biomarkers for translational research
- Develop barcoding panels for immunophenotype analysis of patient samples using time-of-flight mass cytometry (CyTOF analysis)
- Identify unique cellular components/subsets and map interrelated signaling networks
- Track distinct cellular populations in samples following identification by barcoding
LOCATION: 7th floor of the BJC Institute of Health, Washington University School of Medicine
PRICING: Please contact the core for current pricing of services offered.
TO ACCESS: Contact Tina Marti 747-7584
NIH PUBLIC ACCESS POLICY: As of April 7, 2008, the NIH requires investigators with a publication using Siteman (or other NIH-funded) shared resources to submit (or have submitted for them) their final, peer reviewed manuscripts to PubMed Central(PMC) upon acceptance of publication, to be made publicly available within 12 months of publication. Many journals automatically submit these for authors, but Washington University also has assistance available through the Becker Medical Library. Please see http://publicaccess.nih.gov/FAQ.htm#b7 or http://becker.wustl.edu/classes-consulting/specialized-expertise/nih-public-access-policy for more information.
PUBLICATION ACKNOWLEDGEMENT: If research supported by the Immunomonitoring Laboratory results in publication, please acknowledge this support by including the following in your publication(s):
We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO., for the use of the Immunomonitoring Laboratory, which provided __________ service. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA091842.